decrypt.co
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
Moderna's stock surged 131% after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in resected melanoma.
Biotechnology
Stories tagged “Biotechnology.”
23 stories
arynews.tv
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients
Amylyx Pharmaceuticals' experimental drug avexitide sharply reduced dangerously low blood sugar episodes in a late-stage trial of patients who underwent weight-loss surgery.
wired.com
There’s a New Link Between Gut Health and Alzheimer’s Disease
Scientists have identified imidazole propionate (ImP), a molecule produced by certain gut bacteria, as a potential link between the gut microbiome and Alzheimer's disease.
seekingalpha.com
Prime Medicine: Soon In The Clinic
Prime Medicine trades at a $548M valuation despite a 54% stock decline from 52-week highs. They have continued to clear IND/CTA and receive RMAT designation for their gene-editing pipeline targeting liver, lung, and immunology/oncology indications.
fool.com
10x Genomics (TXG) Q2 2026 Earnings Call Transcript
10x Genomics (TXG) reported Q2 2026 earnings, raising full-year revenue guidance despite expected sequential decline in the third quarter. Booked orders for the new Atera platform have surpassed the 2026 shipment target, though manufacturing capacity limits remain a const…
straitstimes.com
NUS researchers brandish light beams for biotechnology breakthrough
Researchers from the National University of Singapore (NUS) have developed a red light-responsive protein called y-iLight that controls gene activity in yeast without extra chemicals. This breakthrough makes biomanufacturing more reliable and eco-friendly.
bbc.com
Artificial Intelligence Designs New, Replicable Viruses for First Time
Researchers at Stanford University have successfully designed new, replicable viruses using artificial intelligence. This breakthrough marks the first time AI has designed a complete virus genome. The team created 16 new viruses that target bacteria, with no threat to hum…
tehrantimes.com
Iran Health Expo to kick off on August 8
The 27th Iran Health International Exhibition will be held from August 8 to 11 at the Tehran Permanent International Fairground, showcasing the latest technological achievements in the healthcare sector.
technologyreview.com
Montana’s new “right to try” law can’t come soon enough for some
A Montana law allows people to access unapproved drugs, which could help a father, Kris DeVault, get his son, Brody, a treatment for a rare condition. However, the law has its limitations, and DeVault is considering other options.
finance.yahoo.com
Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential
Buckley Capital Advisors highlighted Liquidia Corporation (NASDAQ: LQDA) in its second-quarter 2026 investor letter, citing 50%+ upside on Yutrepia ruling and buyout potential.
technologyreview.com
The Quest to Keep Organs Alive Outside the Body
A team of researchers has successfully preserved pig kidneys at -4°C for days, a major breakthrough in the quest to keep organs alive outside the body. This achievement could lead to the development of organ banks, where human organs can be preserved for days, weeks, or e…
scmp.com
Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
Wall Street funds, including BlackRock and JPMorgan Chase, have increased their stakes in Chinese pharmaceutical contractor WuXi AppTec, betting on a surge in weight-loss drug manufacturing orders.
seekingalpha.com
CRISPR Therapeutics: A Catalyst-Rich 12 Months Ahead
CRISPR Therapeutics offers a diversified gene-editing pipeline with CASGEVY as its lead approved asset and multiple upcoming catalysts. The company's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are im…
fool.com
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals for $10 billion, gaining access to products for endocrine diseases and a pipeline of promising candidates. This move diversifies Vertex's portfolio and could drive strong financial results.
seekingalpha.com
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness.
seekingalpha.com
XPH: Healthcare Dashboard For July
Pharmaceuticals/biotechnology valuations and quality are near 11-year historical baselines, while healthcare equipment appears undervalued and life science tools least attractive. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharmaceutical exposure with a …
finance.yahoo.com
2 Beaten-Down Stocks That Still Aren't Worth Buying
Two beaten-down stocks, Recursion Pharmaceuticals and Sarepta Therapeutics, are not worth buying despite their potential for long-term gains. Both companies face significant challenges, including clinical and regulatory setbacks, and are not attractive investments for mos…
arxiv.org
Design-CP: Context Parallelism for Design of Protein Nanoparticles
The paper introduces Design-CP, a method using context-parallel inference strategies for RFdiffusion 3 to overcome GPU memory limitations in designing large multimeric protein complexes. It enables the all-atom design of complex protein nanoparticles like icosahedral and …
tehrantimes.com
Iran, China to support joint research projects
Iran and China, through their respective science foundations, will jointly fund 15 research projects in critical areas like water, energy, and biotechnology, with each project receiving approximately $28,800 over three years. This initiative follows their sixth joint call…
en.mehrnews.com
Iran launches umbilical cord cell therapy for osteoarthritis
Iran has launched a cell therapy product made from umbilical cord-derived stem cells for treating osteoarthritis. The product, WhartoCell, was developed by researchers at Royan Institute.
seekingalpha.com
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
Allarity Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where CEO Thomas Jensen discussed the company's progress and future plans. The meeting included a presentation by CFO Jeffrey Ervin.
fool.com
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Zenas BioPharma's CEO, Leon Molder, purchased 60,000 company shares at a weighted average price of $16.88 per share. This transaction suggests a bullish outlook towards the stock.
news.crunchbase.com
Boston Startup Fundraising Looks Strong Only By Pre-AI Parameters
Boston startups raised about $7.8 billion so far this year, but the gain looks modest beside the AI-fueled boom concentrated in San Francisco.